SUNScholar will be down for routine maintenance from 2018-12-11 10:00 SAST.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation

Paredes, Roger ; Tzou, Philip L. ; Van Zyl, Gert ; Barrow, Geoff ; Camacho, Ricardo ; Carmona, Sergio ; Grant, Philip M. ; Gupta, Ravindra K. ; Hamers, Raph L. ; Harrigan, P. Richard ; Jordan, Michael R. ; Kantor, Rami ; Katzenstein, David A. ; Kuritzkes, Daniel R. ; Maldarelli, Frank ; Otelea, Dan ; Wallis, Carole L. ; Schapiro, Jonathan M. ; Shafer, Robert W. (2017-07-28)

CITATION: Paredes, R., et al. 2018. Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS ONE, 12(7):e0181357, doi:10.1371/journal.pone.0181357.

The original publication is available at https://journals.plos.org/plosone

Article

Introduction: HIV-1 genotypic resistance test (GRT) interpretation systems (IS) require updates as new studies on HIV-1 drug resistance are published and as treatment guidelines evolve. Methods: An expert panel was created to provide recommendations for the update of the Stanford HIV Drug Resistance Database (HIVDB) GRT-IS. The panel was polled on the ARVs to be included in a GRT report, and the drug-resistance interpretations associated with 160 drug-resistance mutation (DRM) pattern-ARV combinations. The DRM pattern-ARV combinations included 52 nucleoside RT inhibitor (NRTI) DRM pattern-ARV combinations (13 patterns x 4 NRTIs), 27 nonnucleoside RT inhibitor (NNRTI) DRM pattern-ARV combinations (9 patterns x 3 NNRTIs), 39 protease inhibitor (PI) DRM pattern-ARV combinations (13 patterns x 3 PIs) and 42 integrase strand transfer inhibitor (INSTI) DRM pattern-ARV combinations (14 patterns x 3 INSTIs). Results: There was universal agreement that a GRT report should include the NRTIs lamivudine, abacavir, zidovudine, emtricitabine, and tenofovir disoproxil fumarate; the NNRTIs efavirenz, etravirine, nevirapine, and rilpivirine; the PIs atazanavir/r, darunavir/r, and lopinavir/r (with “/r” indicating pharmacological boosting with ritonavir or cobicistat); and the INSTIs dolutegravir, elvitegravir, and raltegravir. There was a range of opinion as to whether the NRTIs stavudine and didanosine and the PIs nelfinavir, indinavir/r, saquinavir/r, fosamprenavir/r, and tipranavir/r should be included. The expert panel members provided highly concordant DRM pattern-ARV interpretations with only 6% of NRTI, 6% of NNRTI, 5% of PI, and 3% of INSTI individual expert interpretations differing from the expert panel median by more than one resistance level. The expert panel median differed from the HIVDB 7.0 GRT-IS for 20 (12.5%) of the 160 DRM pattern-ARV combinations including 12 NRTI, two NNRTI, and six INSTI pattern-ARV combinations. Eighteen of these differences were updated in HIVDB 8.1 GRT-IS to reflect the expert panel median. Additionally, HIVDB users are now provided with the option to exclude those ARVs not considered to be universally required. Conclusions: The HIVDB GRT-IS was updated through a collaborative process to reflect changes in HIV drug resistance knowledge, treatment guidelines, and expert opinion. Such a process broadens consensus among experts and identifies areas requiring further study.

Please refer to this item in SUNScholar by using the following persistent URL: http://hdl.handle.net/10019.1/104679
This item appears in the following collections: